A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 2, 2016, Pages 338-343

  Carroll, Kelli J ^a   Makarewich, Catherine A ^a   McAnally, John ^a   Anderson, Douglas M ^a   Zentilin, Lorena ^b   Liu, Ning ^a   Giacca, Mauro ^b   Bassel Duby, Rhonda ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Cardioediting; Cardiovascular pathology; CRISPR associated endonuclease; Gene knockdown; Transgenic mouse

Indexed keywords

CRISPR ASSOCIATED PROTEIN; ENDONUCLEASE; GENOMIC DNA; GUIDE RNA; MYH6 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR; MYH6 PROTEIN, MOUSE; MYOSIN HEAVY CHAIN;

ADENO ASSOCIATED VIRUS 9; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS ASSOCIATED CAS 9; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENOME ANALYSIS; HEART; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; LETHALITY; MOUSE; NONHUMAN; NULL ALLELE; POSTNATAL CARE; PRIORITY JOURNAL; RNA EDITING; TISSUE SPECIFICITY; TRANSGENIC MOUSE; ZYGOTE; AGING; ANIMAL; ANTIBODY SPECIFICITY; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL SEPARATION; COMPLICATION; CRISPR CAS SYSTEM; DEPENDOPARVOVIRUS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY;

AGING; ANIMALS; CARDIOMEGALY; CELL SEPARATION; CRISPR-CAS SYSTEMS; DEPENDOVIRUS; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; HEART FAILURE; MICE, TRANSGENIC; MODELS, ANIMAL; MYOCARDIUM; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; ORGAN SPECIFICITY; RNA, GUIDE;

EID: 84954521442     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1523918113     Document Type: Article

References (39)

1. Capecchi MR (2005) Gene targeting in mice: Functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 6(6):507-512.
2. Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.
3. Barrangou R, et al. (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709-1712.
4. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
5. Jinek M, et al. (2013) RNA-programmed genome editing in human cells. eLife 2:e00471.
6. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
7. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121): 823-826.
8. Bibikova M, Golic M, Golic KG, Carroll D (2002) Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161(3):1169-1175.
9. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262-1278.
10. Cong L, Zhang F (2015) Genome engineering using CRISPR-Cas9 system. Methods Mol Biol 1239:197-217.
11. Ran FA, et al. (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281-2308.
12. Hwang WY, et al. (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31(3):227-229.
13. Hwang WY, et al. (2013) Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS One 8(7):e68708.
14. Shen B, et al. (2013) Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23(5):720-723.
15. Wang H, et al. (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910-918.
16. Niu Y, et al. (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNAmediated gene targeting in one-cell embryos. Cell 156(4):836-843.
17. Gulick J, Subramaniam A, Neumann J, Robbins J (1991) Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 266(14):9180-9185.
18. Platt RJ, et al. (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440-455.
19. Zacchigna S, Zentilin L, Giacca M (2014) Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res 114(11):1827-1846.
20. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA (1997) Myosin heavy chain gene expression in human heart failure. J Clin Invest 100(9):2362-2370.
21. Gupta MP (2007) Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 43(4):388-403.
22. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69(2):318-328.
23. Kehat I, Molkentin JD (2010) Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122(25):2727-2735.
24. Canver MC, et al. (2014) Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem 289(31):21312-21324.
25. Pugach EK, Richmond PA, Azofeifa JG, Dowell RD, Leinwand LA (2015) Prolonged Cre expression driven by the α-myosin heavy chain promoter can be cardiotoxic. J Mol Cell Cardiol 86:54-61.
26. Huang WY, Aramburu J, Douglas PS, Izumo S (2000) Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat Med 6(5):482-483.
27. Slaymaker IM, et al. (2015) Rationally engineered Cas9 nucleases with improved specificity. Science, in press.
28. Carniel E, et al. (2005) Alpha-myosin heavy chain: A sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112(1):54-59.
29. Jones WK, et al. (1996) Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest 98(8):1906-1917.
30. Long C, et al. (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345(6201):1184-1188.
31. Schwank G, et al. (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6):653-658.
32. Yin H, et al. (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551-553.
33. Baltimore D, et al. (2015) Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348(6230):36-38.
34. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (2015) Don't edit the human germ line. Nature 519(7544):410-411.
35. Senís E, et al. (2014) CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J 9(11):1402-1412.
36. Inagaki K, et al. (2006) Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14(1):45-53.
37. Zentilin L, Marcello A, Giacca M (2001) Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 75(24):12279-12287.
38. Makarewich CA, et al. (2014) Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ Res 115(6):567-580.
39. Jaleel N, et al. (2008) Ca2+ influx through T- and L-type Ca2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res 103(10):1109-1119.